PLOS One
Using dapagliflozin to reduce symptoms in transthyretin cardiac amyloidosis: An n-of-1 trial series pilot study
Non-randomised trial in 7 peopleInterventions
30 weeks, registered EUCTR2021-003674-32, declared ties to: AstraZeneca, Bayer, Pfizer and 8 more
- Dapagliflozin
- Transthyretin amyloid cardiomyopathy
- 6-minute walking test distance
- Kansas City Cardiomyopathy Questionnaire total symptom score
- NT-proBNP
- Humans
The paper
Umeå University; Karolinska Institutet
PLOS One, 7 Oct 2026
